Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children

Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high‐p...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of clinical pharmacology Vol. 84; no. 1; pp. 197 - 203
Main Authors Allegra, Sarah, Fatiguso, Giovanna, De Francia, Silvia, Favata, Fabio, Pirro, Elisa, Carcieri, Chiara, De Nicolò, Amedeo, Cusato, Jessica, Di Perri, Giovanni, D'Avolio, Antonio
Format Journal Article
LanguageEnglish
Published England John Wiley and Sons Inc 01.01.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high‐performance liquid chromatography–mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females (P < 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
UNI EN ISO UNI EN ISO 9001:2008 and 13485:2012 (CE‐IVD) Certified Laboratory; Certificate No. IT‐64386. Certification for: “DESIGN, DEVELOPMENT AND APPLICATION OF DETERMINATION METHODS FOR ANTI‐INFECTIVE DRUGS. PHARMACOGENETIC ANALYSES”.
ISSN:0306-5251
1365-2125
1365-2125
DOI:10.1111/bcp.13401